Sipavibart
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | SARS-CoV-2 |
| Clinical data | |
| Trade names | Kavigale |
| Other names | AZD-3152 |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Sipavibart, sold under the brand name Kavigale, is a medication used for the prevention of COVID-19 in people who are immunocompromised. Sipavibart is a recombinant human IgG1 monoclonal antibody that provides passive immunization against SARS-CoV-2 by binding its spike protein receptor binding domain.
Sipavibart was authorized for medical use in the European Union in January 2025.